Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.49 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PADI1 | Q9ULC6 | 2/20 | 0.43 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PADI3 | Q9ULW8 | 1/20 | 0.41 |
| ▸ | TMPRSS11D | O60235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8526415 | 0.89 | TLR2 (0.56) | TLR2CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL8526421 | 0.89 | TLR2 (0.56) | TLR2CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL7272134 | 0.85 | TLR2 (0.58) | TLR2 | |
| SCHEMBL15669228 | 0.83 | TLR2 (0.43) | TLR2 | |
| SCHEMBL15669229 | 0.83 | TLR2 (0.43) | TLR2 | |
| SCHEMBL26523520 | 0.82 | CYP1A2 (0.47) | TLR2CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL1688370 | 0.82 | ALDH1A1 (0.42) | TLR2 | |
| SCHEMBL10070276 | 0.82 | ALDH1A1 (0.42) | TLR2 | |
| SCHEMBL27656566 | 0.81 | TLR2 (0.51) | TLR2TMPRSS11D | |
| SCHEMBL2251929 | 0.81 | MEP1B (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093276-B2 | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | APP, BACE1, APBA1 | TLR2 4009/4885PDE4A 719/4885PADI1 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.